CoChat

Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature

Tibble, Courtney Aavang, Cavaiola, Tricia Santos, Henry, Robert R · 2013 · Expert Review of Endocrinology & Metabolism
Cited by 25

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

With the rapidly rising incidence of Type 2 diabetes and an increasing variety of medications available for treatment, choosing the ideal regimen for patients can be challenging. Longer-acting glucagon-like peptide-1 (GLP-1) receptor agonists and devices have been recently developed and include once-weekly exenatide, dulaglutide, albiglutide, semaglutide and miniosmotic pump ITCA650. Some of the attractive qualities of the GLP-1 receptor agonist class include its association with weightloss and potential for cardiovascular benefits. The longer-acting forms have been shown in several studies to produce equal or greater reduction in A1c and weight compared with the standard twice-daily formulation of exenatide. They also result in lower reported incidence of nausea, in the setting of a less frequent injection schedule that would be desirable to many diabetic patients. There are emerging data to suggest patients treated with longer-acting GLP-1 receptor agonists have improved cardiac parameters, some of which are independent of weight and A1c reductions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1586/eem.13.20

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Research works printed but not linked: 44

  1. Shaw, 2010, Diabetes Res. Clin. Pract., 87, 4, 10.1016/j.diabres.2009.10.007 · DOI · Paper page
  2. Mokdad, 2003, JAMA, 289, 76, 10.1001/jama.289.1.76 · DOI · Paper page
  3. Drucker, 2006, Lancet, 368, 1696, 10.1016/S0140-6736(06)69705-5 · DOI · Paper page
  4. Holst, 2008, Trends Mol. Med., 14, 161, 10.1016/j.molmed.2008.01.003 · DOI · Paper page
  5. Robles, 2009, Drug Des. Devel. Ther., 3, 219, 10.2147/DDDT.S3321 · DOI
  6. Chia, 2008, J. Clin. Endocrinol. Metab., 93, 3703, 10.1210/jc.2007-2109 · DOI · Paper page
  7. Montanya, 2009, Clin. Ther., 31, 2472, 10.1016/j.clinthera.2009.11.034 · DOI
  8. 10.2337/dc06-2375 · DOI · Paper page
  9. Buse, 2010, Diabetes Care, 33, 1255, 10.2337/dc09-1914 · DOI · Paper page
  10. Bergenstal, 2010, Lancet, 376, 431, 10.1016/S0140-6736(10)60590-9 · DOI · Paper page
  11. Wysham, 2011, Diabet. Med., 28, 705, 10.1111/j.1464-5491.2011.03301.x · DOI · Paper page
  12. Russell-Jones, 2012, Diabetes Care, 35, 252, 10.2337/dc11-1107 · DOI · Paper page
  13. Rosenstock, 2009, Diabetes Care, 32, 1880, 10.2337/dc09-0366 · DOI · Paper page
  14. Glaesner, 2010, Diabetes Metab. Res. Rev., 26, 287, 10.1002/dmrr.1080 · DOI · Paper page
  15. Toft-Nielsen, 1999, Diabetes Care, 22, 1137, 10.2337/diacare.22.7.1137 · DOI · Paper page
  16. Davies, 2012, Diabetes Obes. Metab., 14, 882, 10.1111/j.1463-1326.2012.01595.x · DOI · Paper page
  17. Minze, 2011, J. Fam. Pract., 60, 577
  18. Aroda, 2011, Postgrad. Med., 123, 228, 10.3810/pgm.2011.09.2479 · DOI · Paper page
  19. Buse, 2013, Lancet, 381, 117, 10.1016/S0140-6736(12)61267-7 · DOI · Paper page
  20. Aroda, 2012, Clin. Ther., 34, 1247.e22, 10.1016/j.clinthera.2012.04.013 · DOI · Paper page
  21. Best, 2009, Diabet. Med., 26, 722, 10.1111/j.1464-5491.2009.02752.x · DOI · Paper page
  22. Tomkin, 2009, Curr. Opin. Mol. Ther., 11, 579
  23. Bush, 2009, Diabetes. Obes. Metab., 11, 498, 10.1111/j.1463-1326.2008.00992.x · DOI · Paper page
  24. Rosenstock, 2010, Drugs Fut, 35, 701, 10.1358/dof.2010.035.09.1516042 · DOI
  25. Barrington, 2011, Diabetes. Obes. Metab., 13, 434, 10.1111/j.1463-1326.2011.01365.x · DOI
  26. Umpierrez, 2011, Diabetes. Obes. Metab., 13, 418, 10.1111/j.1463-1326.2011.01366.x · DOI
  27. Raz, 2012, Diabetes Care, 35, 485, 10.2337/dc11-1942 · DOI · Paper page
  28. Fineman, 2012, Diabetes. Obes. Metab., 14, 546, 10.1111/j.1463-1326.2012.01561.x · DOI
  29. Blonde, 2009, Diabetes. Obes. Metab., 11, 26, 10.1111/j.1463-1326.2009.01075.x · DOI · Paper page
  30. Ratner, 2011, Cardiovasc. Diabetol., 10, 22, 10.1186/1475-2840-10-22 · DOI
  31. Haffner, 1998, N. Engl. J. Med., 339, 229, 10.1056/NEJM199807233390404 · DOI · Paper page
  32. 10.2337/diabetes.54.1.146 · DOI · Paper page
  33. Sivertsen, 2012, Nat. Rev. Cardiol., 9, 209, 10.1038/nrcardio.2011.211 · DOI
  34. Kavianipour, 2003, Peptides, 24, 569, 10.1016/S0196-9781(03)00108-6 · DOI
  35. Nikolaidis, 2004, Circulation, 110, 955, 10.1161/01.CIR.0000139339.85840.DD · DOI · Paper page
  36. 10.3132/dvdr.2004.005 · DOI · Paper page
  37. Bao, 2011, PLoS ONE, 6, e23570, 10.1371/journal.pone.0023570 · DOI · Paper page
  38. Best, 2011, Diabetes Care, 34, 90, 10.2337/dc10-1393 · DOI · Paper page
  39. Monami, 2011, Exp. Diabetes Res., 2011, 215764
  40. Okerson, 2012, Cardiovasc. Ther., 30, e146, 10.1111/j.1755-5922.2010.00256.x · DOI · Paper page
  41. Robinson, 2013, Br. Med. J., 3
  42. Singh, 2013, JAMA Intern. Med., 25, 1
  43. Guillermin, 2012, J. Med. Econ., 15, 654, 10.3111/13696998.2012.670677 · DOI
  44. Gaebler, 2012, Vasc. Health Risk Manag., 8, 255, 10.2147/VHRM.S28744 · DOI

Cited by

See all 25

Metadata

Authors
Tibble, C. A., Cavaiola, T. S., & Henry, R. R.
Venue
Expert Review of Endocrinology & Metabolism
Published
2013-05
Volume
8
Issue
3
Pages
247-259
ISSN
  • 1744-6651 (ISSN-L)
  • 1744-8417
OpenAlex
W2105554519
Cited by
25
References
19
FWCI
2.59
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature. https://app.cochat.ai/papers/10.1586/eem.13.20
The paper
Tibble, C. A., Cavaiola, T. S., & Henry, R. R. (2013). Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature. Expert Review of Endocrinology & Metabolism. https://doi.org/10.1586/eem.13.20

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.